These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8379434)

  • 61. The targeting of CD4+ T lymphocytes to a B cell lymphoma. A comparison of anti-CD3-anti-idiotype antibody conjugates and antigen-anti-idiotype antibody conjugates.
    Gravelle M; Ochi A
    J Immunol; 1989 Jun; 142(11):4079-84. PubMed ID: 2523940
    [TBL] [Abstract][Full Text] [Related]  

  • 62. From dendritic cells to tumour vaccines.
    Hamblin TJ
    Lancet; 1996 Mar; 347(9003):705-6. PubMed ID: 8601996
    [No Abstract]   [Full Text] [Related]  

  • 63. Effects of CD40 stimulation in the prevention of human EBV-lymphomagenesis.
    Funakoshi S; Taub DD; Asai O; Hirano A; Ruscetti FW; Longo DL; Murphy WJ
    Leuk Lymphoma; 1997 Jan; 24(3-4):187-99. PubMed ID: 9156649
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
    Zhang Y; Renkvist N; Sun Z; Schuler-Thurner B; Glaichenhaus N; Schuler G; Boon T; van der Bruggen P; Colau D
    Eur J Immunol; 2005 Apr; 35(4):1066-75. PubMed ID: 15756643
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Induction of vigorous helper and cytotoxic T cell as well as B cell responses by dendritic cells expressing a modified antigen targeting receptor-mediated internalization pathway.
    You Z; Huang XF; Hester J; Rollins L; Rooney C; Chen SY
    J Immunol; 2000 Oct; 165(8):4581-91. PubMed ID: 11035100
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide.
    van Bergen J; Camps M; Offringa R; Melief CJ; Ossendorp F; Koning F
    Cancer Res; 2000 Nov; 60(22):6427-33. PubMed ID: 11103809
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions.
    Spendlove L; Li L; Potter V; Christiansen D; Loveland BE; Durrant LG
    Eur J Immunol; 2000 Oct; 30(10):2944-53. PubMed ID: 11069077
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Monoclonal antibodies raised against the idiotype of the murine B cell lymphoma, BCL1 act primarily with heavy chain determinants.
    George AJ; McBride HM; Glennie MJ; Smith LJ; Stevenson FK
    Hybridoma; 1991 Apr; 10(2):219-27. PubMed ID: 1908435
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells.
    Hsu FJ; Benike C; Fagnoni F; Liles TM; Czerwinski D; Taidi B; Engleman EG; Levy R
    Nat Med; 1996 Jan; 2(1):52-8. PubMed ID: 8564842
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein.
    Kaminski MS; Kitamura K; Maloney DG; Levy R
    J Immunol; 1987 Feb; 138(4):1289-96. PubMed ID: 3492546
    [TBL] [Abstract][Full Text] [Related]  

  • 71. B cell response to tumor antigens is associated with depletion of B progenitors in murine colocarcinoma.
    Kirman I; Huang EH; Whelan RL
    Surgery; 2004 Mar; 135(3):313-8. PubMed ID: 14976482
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
    da Cunha A; Antoniazi Michelin M; Cândido Murta EF
    Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Anti-Ig as a model for MHC-restricted help.
    Parker DC; Tony HP
    Ann Immunol (Paris); 1984; 135D(1):89-91. PubMed ID: 6237605
    [No Abstract]   [Full Text] [Related]  

  • 74. Idiotypic antibody immunotherapy of cancer.
    Chatterjee MB; Foon KA; Köhler H
    Cancer Immunol Immunother; 1994 Feb; 38(2):75-82. PubMed ID: 8306369
    [No Abstract]   [Full Text] [Related]  

  • 75. CD5 B cells, a fetal B cell lineage.
    Hardy RR; Hayakawa K
    Adv Immunol; 1994; 55():297-339. PubMed ID: 7508175
    [No Abstract]   [Full Text] [Related]  

  • 76. Antigen-driven stimulation of B-lymphocytes in vitro.
    Hu Z
    Methods Mol Biol; 2002; 178():113-9. PubMed ID: 11968480
    [No Abstract]   [Full Text] [Related]  

  • 77. Mechanisms of resistance against B-cell malignancies induced by vaccination against the immunoglobulin receptor: the case for T-cell immunity.
    Sternas LA; Weeks SW; Kwak LW
    Cancer Treat Res; 1999; 99():267-73. PubMed ID: 9891871
    [No Abstract]   [Full Text] [Related]  

  • 78. Neoplastic B cells as targets for antibody-ricin A chain immunotoxins.
    Vitetta ES; Krolick KA; Uhr JW
    Immunol Rev; 1982; 62():159-83. PubMed ID: 7042537
    [No Abstract]   [Full Text] [Related]  

  • 79. Tumor inhibition by chlorambucil covalently linked to antitumor globulin.
    Tai J; Blair AH; Ghose T
    Eur J Cancer (1965); 1979 Nov; 15(11):1357-63. PubMed ID: 527626
    [No Abstract]   [Full Text] [Related]  

  • 80. Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment.
    Saxena M; Bhardwaj N
    Trends Cancer; 2018 Feb; 4(2):119-137. PubMed ID: 29458962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.